CURRENT CASE STUDIES

Glioblastoma is one of the most common and challenging primary brain tumors in adults. It originates from glial cells in the brain and is known for its rapid growth and tendency to infiltrate surrounding tissue, making complete removal difficult. Symptoms can include headaches, seizures, cognitive changes, and neurological deficits, depending on the tumor's location. While standard treatments can help manage the disease, many patients seek targeted therapies to improve outcomes and quality of life.

CAR-T (Chimeric Antigen Receptor T) cell therapy is a groundbreaking immunotherapy that has shown potential in treating SLE by targeting B cells, which play a critical role in the pathogenesis of the disease. In SLE, B cells produce autoantibodies that attack the body’s tissues, leading to chronic inflammation and organ damage. CAR-T therapy works by engineering T cells to express a receptor (CAR) that specifically targets CD19, a marker on B cells, leading to the destruction of these harmful B cells.

CAR-T cells targeting CD19+ B cells provide a more effective and sustained depletion of B cells compared to other therapies, which targets CD20 but fails to eliminate long-lived plasma cells. This profound B-cell depletion can lead to remission of SLE symptoms by eliminating the cells responsible for autoantibody production. Studies also explore CAR-Treg (CAR-T cells designed to regulate immune responses) to restore immune tolerance and reduce autoimmune activity.